Search Results
You are looking at 1 - 10 of 10 items for
- Author: Dong Li x
- Refine by access: All content x
Search for other papers by Yan-ping Xu in
Google Scholar
PubMed
Department of Neonatology, Department of Neonatology, Department of Pediatric Neurology, Central Laboratory, Department of Endocrinology, The Children's Hospital, Zhejiang University School of Medicine and Zhejiang Key Laboratory for Diagnosis and Therapy of Neonatal Diseases, Hangzhou 310003, China
Search for other papers by Jia-jun Zhu in
Google Scholar
PubMed
Search for other papers by Fen Cheng in
Google Scholar
PubMed
Search for other papers by Ke-wen Jiang in
Google Scholar
PubMed
Search for other papers by Wei-zhong Gu in
Google Scholar
PubMed
Search for other papers by Zheng Shen in
Google Scholar
PubMed
Search for other papers by Yi-dong Wu in
Google Scholar
PubMed
Search for other papers by Li Liang in
Google Scholar
PubMed
Search for other papers by Li-zhong Du in
Google Scholar
PubMed
Effective treatment and/or prevention strategies for neonatal persistent pulmonary hypertension of the newborn (PPHN) have been an important topic in neonatal medicine. However, mechanisms of impaired pulmonary vascular structure in hypoxia-induced PPHN are poorly understood and consequently limit the development of effective treatment. In this study, we aimed to explore the molecular signaling cascades in the lungs of a PPHN animal model and used primary cultured rat pulmonary microvascular endothelial cells to analyze the physiological benefits of ghrelin during the pathogenesis of PPHN. Randomly selected newborn rats were exposed to hypoxia (10–12%) or room air and received daily s.c. injections of ghrelin (150 μg/kg) or saline. After 2 weeks, pulmonary hemodynamics and morphometry were assessed in the rats. Compared with the control, hypoxia increased pulmonary arterial pressure, right ventricle (RV) hypertrophy, and arteriolar wall thickness. Ghrelin treatment reduced both the magnitude of PH and the RV/(left ventricle+septum (Sep)) weight ratio. Ghrelin protected neonatal rats from hypoxia-induced PH via the upregulation of phosphorylation of glycogen synthase kinase 3β (p-GSK3β)/β-catenin signaling and associated with β-catenin translocation to the nucleus in the presence of growth hormone secretagogue receptor-1a. Our findings suggest that s.c. administration of ghrelin improved PH and attenuated pulmonary vascular remodeling after PPHN. These beneficial effects may be mediated by the regulation of p-GSK3β/β-catenin expression. We propose ghrelin as a novel potential therapeutic agent for PPHN.
Search for other papers by Dong Li in
Google Scholar
PubMed
Search for other papers by Chenhao Cao in
Google Scholar
PubMed
Search for other papers by Zhuofan Li in
Google Scholar
PubMed
Search for other papers by Zhiyong Chang in
Google Scholar
PubMed
Search for other papers by Ping Cai in
Google Scholar
PubMed
Search for other papers by Chenxi Zhou in
Google Scholar
PubMed
Search for other papers by Jun Liu in
Google Scholar
PubMed
Search for other papers by Kaihua Li in
Google Scholar
PubMed
Search for other papers by Bin Du in
Google Scholar
PubMed
Icariside II, a flavonoid glycoside, is the main component found invivo after the administration of Herba epimedii and has shown some pharmacological effects, such as prevention of osteoporosis and enhancement of immunity. Increased levels of marrow adipose tissue are associated with osteoporosis. S100 calcium-binding protein A16 (S100A16) promotes the differentiation of bone marrow mesenchymal stem cells (BMSCs) into adipocytes. This study aimed to confirm the anti-lipidogenesis effect of Icariside II in the bone marrow by inhibiting S100A16 expression. We used ovariectomy (OVX) and BMSC models. The results showed that Icariside II reduced bone marrow fat content and inhibited BMSCs adipogenic differentiation and S100A16 expression, which correlated with lipogenesis. Overexpression of S100A16 eliminated the inhibitory effect of Icariside II on lipid formation. β-catenin participated in the regulation adipogenesis mediated by Icariside II/S100A16 in the bone. In conclusion, Icariside II protects against OVX-induced bone marrow adipogenesis by downregulating S100A16, in which β-catenin might also be involved.
Department of Obstetrics and Gynecology, Hainan Medical College, The Affiliated Hospital, Haikou 570102, China
Search for other papers by Ling Wang in
Google Scholar
PubMed
Department of Obstetrics and Gynecology, Hainan Medical College, The Affiliated Hospital, Haikou 570102, China
Search for other papers by Yu-Dong Wang in
Google Scholar
PubMed
Department of Obstetrics and Gynecology, Hainan Medical College, The Affiliated Hospital, Haikou 570102, China
Search for other papers by Wen-Jun Wang in
Google Scholar
PubMed
Department of Obstetrics and Gynecology, Hainan Medical College, The Affiliated Hospital, Haikou 570102, China
Search for other papers by Ying Zhu in
Google Scholar
PubMed
Department of Obstetrics and Gynecology, Hainan Medical College, The Affiliated Hospital, Haikou 570102, China
Search for other papers by Da-Jin Li in
Google Scholar
PubMed
Dehydroepiandrosterone (DHEA) may be a promising agent for postmenopausal osteoporosis (PMO), but its mechanism to modulate osteoblasts (OBs) is yet to be explained. To elucidate the effects of DHEA treatment on the ovariectomized (OVX) mice and its mechanisms, we evaluated the morphology of mice bone tissue and expression of proliferating cell nuclear antigen (PCNA) in the vertebrae-derived OB after having treated the OVX animals with DHEA. The results showed that DHEA administration increased the expression of PCNA in OB and changed the bone tissue morphometry of the PMO model. To further investigate this mechanism, the OB was isolated from neonatal mice calvariae by the enzyme-digested assay, exposed to DHEA, and then analyzed for ultrastructure, DNA content, early apoptotic cells, and phosphorylation of extracellular signal-regulated kinase 1/2. It was found that DHEA promoted proliferation and inhibited apoptosis of OB significantly, via mitogen-activated protein kinase signaling pathway independent of either androgen receptor or estrogen receptor, suggesting that it may exert roles via a DHEA-specific receptor directly, not by way of conversion to androgens or estrogens.
Search for other papers by Rong-Ying Li in
Google Scholar
PubMed
Search for other papers by Xue-Song Li in
Google Scholar
PubMed
Search for other papers by Li Shao in
Google Scholar
PubMed
Search for other papers by Zhi-yuan Wu in
Google Scholar
PubMed
Search for other papers by Wen-Hua Du in
Google Scholar
PubMed
Search for other papers by Sheng-Xian Li in
Google Scholar
PubMed
Search for other papers by Shuang-xia Zhao in
Google Scholar
PubMed
Search for other papers by Ke-min Chen in
Google Scholar
PubMed
Search for other papers by Ming-Dao Chen in
Google Scholar
PubMed
Search for other papers by Huai-Dong Song in
Google Scholar
PubMed
Although circulating ghrelin levels correlate inversely with adiposity at baseline, little is known about the effect of percent visceral adipose tissue value (PVATV) on ghrelin expression and secretion in response to fasting. Our study demonstrated that ghrelin increased with 24-h fasting in rats with the lowest PVATV (less than 6%), after 3 days in rats with intermediate PVATV (6–9%) and 5 days in rats with the highest PVATV (greater than 9%). Ghrelin mRNA in the stomach was increased after 3 days in low-PVATV (5.8±0.9%) rats but not in high-PVATV (14±1.6%) rats. Therefore, both ghrelin secretion and mRNA were delayed in response to fasting in rats with increased visceral fat. In rats matched for PVATV, but with different body weights, the fasting induced similar levels of increased ghrelin while in rats with different PVATV ghrelin secretion was different in response to fasting, even when body weights were matched in two groups. These data suggested that the initial PVATV, not lean mass, was related to the pattern of plasma ghrelin in response to fasting in rats.
Search for other papers by Yueting Dong in
Google Scholar
PubMed
Search for other papers by Zhiye Xu in
Google Scholar
PubMed
Search for other papers by Ziyi Zhang in
Google Scholar
PubMed
Search for other papers by Xueyao Yin in
Google Scholar
PubMed
Search for other papers by Xihua Lin in
Google Scholar
PubMed
Search for other papers by Hong Li in
Google Scholar
PubMed
Search for other papers by Fenping Zheng in
Google Scholar
PubMed
Liver X receptors (LXR) are deemed as potential drug targets for atherosclerosis, whereas a role in adipose tissue expansion and its relation to insulin sensitivity remains unclear. To assess the metabolic effects of LXR activation by the dual LXRα/β agonist T0901317, C57BL/6 mice fed a high-fat diet (HFD) were treated with T0901317 (30 mg/kg once daily by intraperitoneal injection) for 3 weeks. Differentiated 3T3-L1 adipocytes were used for analysing the effect of T0901317 on glucose uptake. The following results were obtained from this study. T0901317 reduced fat mass, accompanied by a massive fatty liver and lower serum adipokine levels in HFD mice. Increased adipocyte apoptosis was found in epididymal fat of T0901317-treated HFD mice. In addition, T0901317 treatment promoted basal lipolysis, but blunted the anti-lipolytic action of insulin. Furthermore, LXR activation antagonised PPARγ target genes in epididymal fat and PPARγ-PPRE-binding activity in 3T3-L1 adipocytes. Although the glucose tolerance was comparable to that in HFD mice, the insulin response during IPGTT was significantly higher and the insulin tolerance was significantly impaired in T0901317-treated HFD mice, indicating decreased insulin sensitivity by T0901317 administration, and which was further supported by impaired insulin signalling found in epididymal fat and decreased insulin-induced glucose uptake in 3T3-L1 adipocytes by T0901317 administration. In conclusion, these findings reveal that LXR activation impairs adipose expansion by increasing adipocyte apoptosis, lipolysis and antagonising PPARγ-mediated transcriptional activity, which contributes to decreased insulin sensitivity in whole body. The potential of LXR activation being a therapeutic target for atherosclerosis might be limited by the possibility of exacerbating insulin resistance.
Search for other papers by He-jun Zhao in
Google Scholar
PubMed
Search for other papers by Xia Jiang in
Google Scholar
PubMed
Search for other papers by Li-juan Hu in
Google Scholar
PubMed
Search for other papers by Lei Yang in
Google Scholar
PubMed
Search for other papers by Lian-dong Deng in
Google Scholar
PubMed
Search for other papers by Ya-ping Wang in
Google Scholar
PubMed
Search for other papers by Zhi-peng Ren in
Google Scholar
PubMed
This study aimed to determine whether and how the glucagon-like peptide 1 receptor (GLP-1R) agonist liraglutide affects the chemoresistance and chemosensitivity of pancreatic cancer cells to gemcitabine in vitro and in vivo. The GLP-1R and protein kinase A (PKA) levels were compared between the human pancreatic cancer cell line PANC-1 and the gemcitabine-resistant cell line PANC-GR. The in vitro effects of liraglutide on the cell proliferation and apoptosis as well as the nuclear factor-kappa B NF-κB expression levels of PANC-GR cells were evaluated. In addition, a mouse xenograft model of human pancreatic cancer was established by s.c. injection of PANC-1 cells, and the effects of liraglutide on the chemosensitivity were evaluated in vitro and in vivo. In contrast to PANC-1 cells, PANC-GR cells exhibited lower expression levels of GLP-1R and PKA. Incubation with liraglutide dose dependently inhibited the growth, promoted the apoptosis, and increased the expression of GLP-1R and PKA of PANC-GR cells. Similar effects of liraglutide were observed in another human pancreatic cancer cell line MiaPaCa-2/MiaPaCa-2-GR. Either the GLP-1R antagonist Ex-9, the PKA inhibitor H89, or the NF-κB activator lipopolysaccharide (LPS) could abolish the antiproliferative and proapoptotic activities of liraglutide. Additionally, each of these agents could reverse the expression of NF-κB and ABCG2, which was decreased by liraglutide treatment. Furthermore, liraglutide treatment increased the chemosensitivity of pancreatic cancer cells to gemcitabine, as evidenced by in vitro and in vivo experiments. Thus, GLP-1R agonists are safe and beneficial for patients complicated with pancreatic cancer and diabetes, especially for gemcitabine-resistant pancreatic cancer.
Shanghai Key Laboratory for Assisted Reproduction and Reproductive Genetics, Shanghai, China
Key Laboratory of Animal Resistance Biology of Shandong Province, College of Life Science, Shandong Normal University, Ji’nan, Shandong, China
Search for other papers by Yachao Zhang in
Google Scholar
PubMed
Shanghai Key Laboratory for Assisted Reproduction and Reproductive Genetics, Shanghai, China
Search for other papers by Jieqiong Yang in
Google Scholar
PubMed
Shanghai Key Laboratory for Assisted Reproduction and Reproductive Genetics, Shanghai, China
Search for other papers by Shijian Lv in
Google Scholar
PubMed
Search for other papers by Dong-Qin Zhao in
Google Scholar
PubMed
Shanghai Key Laboratory for Assisted Reproduction and Reproductive Genetics, Shanghai, China
Search for other papers by Zi-Jiang Chen in
Google Scholar
PubMed
Shanghai Key Laboratory for Assisted Reproduction and Reproductive Genetics, Shanghai, China
Search for other papers by Wei-Ping Li in
Google Scholar
PubMed
Shanghai Key Laboratory for Assisted Reproduction and Reproductive Genetics, Shanghai, China
Key Laboratory of Animal Resistance Biology of Shandong Province, College of Life Science, Shandong Normal University, Ji’nan, Shandong, China
Search for other papers by Cong Zhang in
Google Scholar
PubMed
Preeclampsia (PE) is a pregnancy-induced disorder characterized by hypertension and proteinuria after 20 weeks of gestation, affecting 5–7% of pregnancies worldwide. So far, the etiology of PE remains poorly understood. Abnormal decidualization is thought to contribute to the development of PE. SP1 belongs to the Sp/KLF superfamily and can recruit P300 to regulate the transcription of several genes. SP1 is also very important for decidualization as it enhances the expression of tissue factor. In this study, we investigated the expression of SP1 and P300 in deciduae and their relationship with PE. A total of 42 decidua samples were collected, of which 21 were from normal pregnant (NP) and 21 from severe PE. SP1 and P300 expression in deciduae and the levels of SP1 and P300 in cultured human endometrial stromal cells (hESCs) and primary hESCs during decidualization were determined. To further investigate the role of SP1 and P300 in human decidualization, RNA interference was used to silence SP1 and P300 in hESCs and primary hESCs. The following results were obtained. We found that the expressions of SP1 and P300 were reduced in decidual tissues with PE compared to those from NP. In the in vitro model of induction of decidualization, we found an increase in both SP1 and P300 levels. Silencing of SP1 and P300 resulted in abnormal decidualization and a significant reduction of decidualization markers such as insulin-like growth factor-binding protein1 and prolactin. Furthermore, the expression of vascular endothelial growth factor was also decreased upon SP1 and P300 silencing. Similar results were observed in primary hESCs. Our results suggest that SP1 and P300 play an important role during decidualization. Dysfunction of SP1 and P300 leads to impaired decidualization and might contribute to PE.
Search for other papers by Rihua Zhang in
Google Scholar
PubMed
Search for other papers by Dongming Su in
Google Scholar
PubMed
Search for other papers by Weidong Zhu in
Google Scholar
PubMed
Search for other papers by Qiong Huang in
Google Scholar
PubMed
Search for other papers by Menglan Liu in
Google Scholar
PubMed
Search for other papers by Yi Xue in
Google Scholar
PubMed
Search for other papers by Yuanyuan Zhang in
Google Scholar
PubMed
Search for other papers by Dong li in
Google Scholar
PubMed
Search for other papers by Allan Zhao in
Google Scholar
PubMed
Search for other papers by Yun Liu in
Google Scholar
PubMed
The aim of this study is to determine the effects of E2 on metabolic syndrome and the molecular mechanisms involving S100A16. Ovariectomized (OVX) rat models and mouse embryonic fibroblasts cell models were used. E2 loss in OVX rats induced body weight gain and central abdominal fat accumulation, which were ameliorated by E2 treatment under chow and high-fat diet (HFD) conditions. E2 decreased the expression of the adipocyte marker genes PPAR γ, aP2, C/EBP α, and S100A16. E2 inhibited adipogenesis. Overexpression of S100A16 reversed the E2-induced adipogenesis effect. A luciferase assay showed that E2 inhibited the expression of S100A16. E2 treatment decreased body weight gain and central abdominal fat accumulation under both chow and HFD conditions. Also, E2 suppressed adipogenesis by inhibiting S100A16 expression.
Co-innovation Center of Neuroregeneration, Nantong University, Nantong, Jiangsu, China
Search for other papers by Xueting Wang in
Google Scholar
PubMed
Co-innovation Center of Neuroregeneration, Nantong University, Nantong, Jiangsu, China
Search for other papers by Zhiran Zou in
Google Scholar
PubMed
Co-innovation Center of Neuroregeneration, Nantong University, Nantong, Jiangsu, China
Search for other papers by Zhihui Yang in
Google Scholar
PubMed
Co-innovation Center of Neuroregeneration, Nantong University, Nantong, Jiangsu, China
Search for other papers by Shan Jiang in
Google Scholar
PubMed
Co-innovation Center of Neuroregeneration, Nantong University, Nantong, Jiangsu, China
Search for other papers by Yapeng Lu in
Google Scholar
PubMed
Co-innovation Center of Neuroregeneration, Nantong University, Nantong, Jiangsu, China
Search for other papers by Dan Wang in
Google Scholar
PubMed
Key Laboratory of Neuroregeneration of Jiangsu and Ministry of Education, Nantong, Jiangsu, China
Search for other papers by Zhangji Dong in
Google Scholar
PubMed
Search for other papers by Sha Xu in
Google Scholar
PubMed
Co-innovation Center of Neuroregeneration, Nantong University, Nantong, Jiangsu, China
Search for other papers by Li Zhu in
Google Scholar
PubMed
Hypoxia-inducible factor-1 (HIF1) is a critical transcription factor involved in cell response to hypoxia. Under physiological conditions, its ‘a’ subunit is rapidly degraded in most tissues except testes. HIF1 is stably expressed in Leydig cells, which are the main source of testosterone for male, and might bind to the promoter region of steroidogenic acute regulatory protein (STAR), which is necessary for the testosterone synthesis, according to software analysis. This study aims to identify the binding sites of HIF1 on Star promoter and its transcriptional regulation of STAR to affect testosterone synthesis. Testosterone level and steroid synthesis-related proteins were determined in male Balb/C mice exposed to hypoxia (8% O2). While HIF1 was upregulated, the testosterone level was significantly decreased. This was further confirmed by in vitro experiments with rat primary Leydig cells or TM3 cells exposed to hypoxia (1% O2), CoCl2 or DFX to raise HIF1. The decline of testosterone was reversed by pregnenolone but not cAMP, indicating the cholesterol transport disorder as the main cause. In agreement, STAR expression level was decreased in response to HIF1, while 3b-hydroxysteroid dehydrogenase, 17b-hydroxysteroid dehydrogenase and p450scc did not exhibit significant changes. By ChIP, EMSA supershift and dual-luciferase reporter assays, HIF1 was found to bind to the Star promoter region and repress the expression of STAR. Mutation assays identified three HIF1-binding sites on mouse Star promoter. These findings indicate that HIF1 represses STAR transcription through directly binding to the Staar promoter at −2082/−2078, −2064/−2060 and −1910/−1906, leading to the negative regulation of testosterone synthesis.
Key Laboratory of Laboratory Medicine, Ministry of Education, Wenzhou Medical University, Wenzhou, Zhejiang, China
Search for other papers by Liang Xu in
Google Scholar
PubMed
Search for other papers by Haoran Li in
Google Scholar
PubMed
Search for other papers by Ouyang Zhang in
Google Scholar
PubMed
Search for other papers by Fengming Zhang in
Google Scholar
PubMed
Search for other papers by Menghui Song in
Google Scholar
PubMed
Search for other papers by Mengchen Ma in
Google Scholar
PubMed
Search for other papers by Youjuan Zhao in
Google Scholar
PubMed
Search for other papers by Rongxiu Ding in
Google Scholar
PubMed
Search for other papers by Dandan Li in
Google Scholar
PubMed
Search for other papers by Zhixiong Dong in
Google Scholar
PubMed
Key Laboratory of Laboratory Medicine, Ministry of Education, Wenzhou Medical University, Wenzhou, Zhejiang, China
Search for other papers by Shengnan Jin in
Google Scholar
PubMed
Institute of Molecular and Cell Biology, Agency for Science, Technology and Research (A*STAR), Singapore
Search for other papers by Weiping Han in
Google Scholar
PubMed
Key Laboratory of Laboratory Medicine, Ministry of Education, Wenzhou Medical University, Wenzhou, Zhejiang, China
Search for other papers by Chunming Ding in
Google Scholar
PubMed
The pathogenesis of nonalcoholic steatohepatitis (NASH), a severe stage of nonalcoholic fatty liver disease, is complex and implicates multiple cell interactions. However, therapies for NASH that target multiple cell interactions are still lacking. Melatonin (MEL) alleviates NASH with mechanisms not yet fully understood. Thus, we herein investigate the effects of MEL on key cell types involved in NASH, including hepatocytes, macrophages, and stellate cells. In a mouse NASH model with feeding of a methionine and choline-deficient (MCD) diet, MEL administration suppressed lipid accumulation and peroxidation, improved insulin sensitivity, and attenuated inflammation and fibrogenesis in the liver. Specifically, MEL reduced proinflammatory cytokine expression and inflammatory signal activation and attenuated CD11C+CD206– M1-like macrophage polarization in the liver of NASH mice. The reduction of proinflammatory response by MEL was also observed in the lipopolysaccharide-stimulated Raw264.7 cells. Additionally, MEL increased liver fatty acid β-oxidation, leading to reduced lipid accumulation, and restored the oleate-loaded primary hepatocytes. Finally, MEL attenuated hepatic stellate cell (HSC) activation and fibrogenesis in the liver of MCD-fed mice and in LX-2 human HSCs. In conclusion, MEL acts on multiple cell types in the liver to mitigate NASH-associated phenotypes, supporting MEL or its analog as potential treatment for NASH.
